Skip to content
Press Releases

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results
New Data Suggest Veracyte’s Afirma® Gene Expression Classifier Cost-Effectively Resolves Inconclusive Thyroid Nodule FNA Biopsy Results South San Francisco, Calif. --- September 1, 2011 --- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today
View HTML
Toggle Summary New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples
New Data Suggest Veracyte's Molecular Test Improves Accuracy of Thyroid Nodule Diagnosis Using Fine Needle Aspirate (FNA) Samples South San Francisco, Calif.--- PRNewswire ---Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, announced that initial
View HTML
Toggle Summary Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product
Veracyte Completes $28 Million Series B Round – One Step Closer to Commercializing First Molecular Diagnostic Product SOUTH SAN FRANCISCO, Calif.--- BUSINESS WIRE ---Veracyte, Inc. announced today the successful completion of its Series B round, a key milestone toward the company’s first product
View HTML